QurAlis Corporation

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cycle Offers $466m For Vanda, Which Tur

Alzheimer’s disease is top of mind due to the millions of people in need of effective treatments and the rapid rise in the AD population globally – and because the first disease-modifying therapy has

After what seemed like a relatively quiet stretch for venture capital mega-rounds of $100m or more, the pace of large VC financings has picked up in March with five big rounds announced already this m